- Global Pharma News & Resources

Familial Amyloid Cardiomyopathy Treatment Market Size, Share, Global Analysis, Restrains, Segments, Competitive Players, Merger and Regional Outlook to 2026

Familial Amyloid Cardiomyopathy Treatment Market – Insights

Familial amyloid cardiomyopathy (FAC), also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy, is the aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart. The condition is more prevalent in geriatric population. The protein transthyretin amyloid fibrils infiltrates the myocardium, thereby leading to diastolic dysfunction from restrictive cardiomyopathy. This in turn increases the risk of heart failure. V1221, P24S, V20I, A45T, Gly47Val, I68L, L111M, Glu51Gly, and Gln92Lys are some of the mutations in TTR, which are associated with familial amyloid cardiomyopathy. V1221 is the most common mutation and is substitution of isoleucine for valine at position 122 that occurs in high frequency in African-Americans.

Get Sample PDF Brochure with Impact of COVID19:

Genetic tests are recommended for detection of TTR gene. FAC is fatal. Some symptoms of FAC include, weight loss, nausea, fatigue, dizziness and collapse, palpitations, abnormal heart rhythms, disrupted sleep, and angina. Inherited transthyretin gene alteration leads to formation of transthyretin protein in the body, thereby causing FAC. Gene alteration changes the sequence of body proteins. Autosomal dominant allele inherit FAC. The condition can pass to offspring from any one of the parent as only one copy of mutated gene is sufficient for progression of the condition. FAC can lead to heart failure. For instance, according to Amyloidosis Foundation (AF), FAC is a rare disease, affecting 1 per 100,000 population.

Familial Amyloid Cardiomyopathy Treatment Market Taxonomy

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

By Geographic Type

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Familial Amyloid Cardiomyopathy Treatment Market: Drivers

Increasing product approval and launch activities is expected to boost growth of the global familial amyloid cardiomyopathy treatment market. For instance, in 2013, the European Medicines Agency approved tafamids (Vyndaqel), a drug that reduces development of FAC.

Familial Amyloid Cardiomyopathy Treatment Market: Regional Analysis 

Increasing TTR mutation is expected to boost growth of the market in Europe. For instance, according to BioMed Central journal, March 2017, people in Europe had the highest number of TTR mutations, followed by East Asia, North America, Central-South Asia, and Africa.

Familial Amyloid Cardiomyopathy Treatment Market: Competitive Landscape 

Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in June 2017, the U.S. Food and Drug Administration (FDA) granted fast track designation to Pfizer’s tafamidis, an investigational drug for the treatment of FAC. Tafamidis, with trade name VYNDAQEL, was first approved in Europe.

Major players operating the global familial amyloid cardiomyopathy treatment market include Ionis Pharmaceuticals, Inc., AstraZeneca plc., Pfizer Inc., SOM Innovation Biotech, S.L., and Valeant Pharmaceuticals International, Inc.

To understand Research Methodology, please click

Table of Content

Global Familial Amyloid Cardiomyopathy Treatment Market Research Report
Section 1: Global Familial Amyloid Cardiomyopathy Treatment Industry Overview
Section 2: Global Economic Impact on Familial Amyloid Cardiomyopathy Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Familial Amyloid Cardiomyopathy Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Familial Amyloid Cardiomyopathy Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-Mar-2021